SLC9A1 and cervical cancer: Note that the dramatic inhibition on NHE1/V-ATPase activity upon acute Andrographolide treatment is around ≈80%, and that it reverses completely (Figure 4A) in cultured human cervical cancer cells, i.e., HeLa cells.